Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


16th International Conference on Breast Pathology and Cancer Diagnosis

Montreal, Canada

Vinithasree Subbhuraam

Vinithasree Subbhuraam

Cyrcadia Health, USA

Title: Wearable sensor technology for breast health monitoring


Biography: Vinithasree Subbhuraam


The AprísÔ (iTBraÔ, CyrcadiaÔ) wearable sensor technology for breast health monitoring is a dynamic (time-based) thermal differential detection system, which detects abnormal circadian surface temperature changes such as those reported to be associated with breast cancer. Temperature measurements are sequentially taken over time to determine changes in circadian readings indicative of physiological changes in the breast tissue that may be associated with cancer. The AprísÔ consists of three major components: (1) Temperature Sensors (2) Recording device (3) Software for Analysis. The sensors are embedded in two fabric patches that are placed on the breasts. An associated data recorder gathers and transmits raw data to a mobile phone App which in turn transmits the raw data to a cloud-based proprietary analytic software. The user is expected to wear the patches continuously for 2-24hrs. The results of the analysis are transmitted back to the user or the user’s physician. Pilot clinical studies have indicated that the device is useful to detect abnormalities in all types of breast tissue, irrespective of breast density, with potential application for periodic breast health screening. The device was modified to address findings in the pilot study; clinical studies with the current version of AprísÔ are scheduled to begin in May 2019. AprísÔ is a tissue density independent, radiation-free, compression-free, non-invasive, low cost, early risk indication screening system for breast tissue. Early detection of breast cancer has been reported to include monitoring for dense tissue. The US FDA has announced its focus on dense breast tissue regarding breast cancer monitoring and diagnosis. Early dense breast tissue detection systems like AprísÔ have significant potential diagnostic and prognostic implications in conjunction with additional testing to confirm the presence or absence of breast cancer in consultation with the physician. Circadian changes in temperature could be a potentially excellent secondary diagnostic modality for breast cancer detection. We believe this could have a significant impact on the current practices for breast cancer monitoring and diagnosis.